Comparative Pharmacology
Head-to-head clinical analysis: TRI LO ESTARYLLA versus YASMIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TRI LO ESTARYLLA versus YASMIN.
TRI-LO-ESTARYLLA vs YASMIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination oral contraceptive containing ethinyl estradiol and norgestimate. Suppresses gonadotropin secretion, primarily FSH and LH, inhibiting ovulation; increases cervical mucus viscosity, impeding sperm penetration; alters endometrial lining, reducing implantation likelihood.
Combination of ethinyl estradiol and drospirenone suppresses gonadotropins, inhibiting ovulation. Drospirenone has antimineralocorticoid activity, reducing water retention, and antiandrogenic activity.
One tablet (20 mcg ethinyl estradiol/0.1 mg levonorgestrel) orally once daily for 21 days, followed by 7 days of placebo.
One tablet (ethinyl estradiol 0.03 mg / drospirenone 3 mg) orally once daily for 21 days, followed by 7 days of placebo.
None Documented
None Documented
Ethinyl estradiol: 19-24 hours (terminal); Norgestimate: active metabolite norelgestromin 28-38 hours; allows once-daily dosing.
Terminal elimination half-life is approximately 30 hours for drospirenone; steady-state concentration is achieved after 10 days of daily dosing.
Renal: ~40% as metabolites; Fecal: ~30% as metabolites (including ethinyl estradiol conjugates); Biliary: ~20% (enterohepatic recirculation).
Approximately 40% renal and 60% fecal after oral administration; metabolites are excreted as glucuronide and sulfate conjugates.
Category C
Category C
Oral Contraceptive
Oral Contraceptive